Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 4:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 221 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Staphylococcus Aureus Infection Clear all
Completed Not applicable Interventional

A Systematic Oral Care Program in Post-Mechanically Ventilated, Post-Intensive Care Patients

NCT03886623
View directory record Official record
Conditions
Methicillin-resistant Staphylococcus Aureus, Methicillin-Sensitive Staphylococcus Aureus Infection
Interventions
4-day systematic oral hygiene, Standard of Care oral care
Procedure · Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 21, 2019 · Synced Sep 8, 2026, 4:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics of Ascending Single Oral Doses of EDP-322 in Nonfasting and Fasting Healthy Volunteers

NCT00989872
View directory record Official record
Conditions
Skin and Soft Tissue Infections, Methicillin-resistant Staphylococcus Aureus
Interventions
EDP-322
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 45 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2009 · Synced Sep 8, 2026, 4:36 PM EDT
Completed Phase 4 Interventional Results available

Nasal Decolonization for Orthopedic Trauma Patients

NCT04146116
View directory record Official record
Conditions
Surgical Site Infection
Interventions
intranasal povidone-iodine
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Sep 8, 2026, 4:36 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Colonization, Infection, and Molecular Typing of Methicillin-Resistant Staphylococcus Aureus (MRSA) in Children.

NCT00254527
View directory record Official record
Conditions
Methicillin Resistance, Staphylococcus Aureus
Interventions
Not listed
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
3 Months to 12 Years
Enrollment
477 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated May 1, 2007 · Synced Sep 8, 2026, 4:36 PM EDT
Completed Phase 2 Interventional

Nasal Photodisinfection in All Patients Presenting for Surgery for a Wide Range of Surgical Procedures

NCT05090657
View directory record Official record
Conditions
Surgical Site Infections, Nosocomial Infection, Healthcare Associated Infections
Interventions
methylene blue 0.01%/chlorhexidine gluconate 0.25% + light activation
Combination Product
Lead sponsor
Ondine Biomedical Inc.
Industry
Eligibility
18 Years and older
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Savannah, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 21, 2022 · Synced Sep 8, 2026, 4:36 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus

NCT00091819
View directory record Official record
Conditions
Staphylococcal Skin Infection
Interventions
Telavancin, Vancomycin
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
862 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
National City, California
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Sep 8, 2026, 4:36 PM EDT
Not listed Not applicable Interventional

Reducing Intraoperative ESKAPE Transmission Through Use of a Personal Hand Hygiene System

NCT04900298
View directory record Official record
Conditions
Surgical Wound Infection, Cross Infection
Interventions
SafeHaven Automated Hand Hygiene Device
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 99 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Sep 8, 2026, 4:36 PM EDT
Terminated Not applicable Interventional

Targeted Gown and Glove Intervention in Nursing Homes

NCT04200508
View directory record Official record
Conditions
Staphylococcus Aureus, Carbapenem Resistant Gram Negative Bacteria
Interventions
Targeted gown and gloves use
Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 17, 2022 · Synced Sep 8, 2026, 4:36 PM EDT
Terminated Phase 3 Interventional Results available

Direct Lysis of Staph Aureus Resistant Pathogen Trial of Exebacase

NCT04160468
View directory record Official record
Conditions
Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis
Interventions
Exebacase, Placebo
Drug
Lead sponsor
ContraFect
Industry
Eligibility
12 Years and older
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
55
States / cities
Birmingham, Alabama • Orange, California • Sacramento, California + 47 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Sep 8, 2026, 4:36 PM EDT
Terminated Phase 2 Interventional Results available

Rifabutin Based Therapy for the Eradication of Staphylococcus Aureus Colonization in HIV Infected Adults

NCT00869518
View directory record Official record
Conditions
Staphylococcus Aureus, HIV Infections
Interventions
rifabutin plus trimethoprim sulfamethoxazole, placebo plus trimethoprim-sulfamethoxazole
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 13, 2014 · Synced Sep 8, 2026, 4:36 PM EDT
Terminated No phase listed Observational

Evaluation of Vancomycin Treatment of Infections Due to Staphylococcus Aureus

NCT00862862
View directory record Official record
Conditions
Staphylococcus Aureus
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Sep 8, 2026, 4:36 PM EDT
Completed Phase 2 Interventional Results available

Persistent Methicillin Resistant Staphylococcus Aureus Eradication Protocol (PMEP)

NCT01594827
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Inhaled Vancomycin, Placebo (Sterile Water), Rifampin, Trimethoprim/Sulfamethoxazole (TMP/SMX), Doxycycline, Mupirocin Intranasal Creme, 4% chlorhexidine gluconate liquid skin cleanser
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
12 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
2
States / cities
Baltimore, Maryland • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Sep 8, 2026, 4:36 PM EDT
Active, not recruiting No phase listed Observational

Immune Resolution After Staphylococcus Aureus Bacteremia

NCT01879761
View directory record Official record
Conditions
Immune Response To Sepsis, Staphylococcus Aureus Infection
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 8, 2026, 4:36 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety Study of Brilacidin to Treat Serious Skin Infections

NCT02052388
View directory record Official record
Conditions
Skin Infection, Bacterial Infection
Interventions
Daptomycin, Brilacidin
Drug
Lead sponsor
Cellceutix Corporation
Industry
Eligibility
18 Years to 85 Years
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
4
States / cities
Chula Vista, California • La Mesa, California • Oceanside, California + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Sep 8, 2026, 4:36 PM EDT
Completed Phase 3 Interventional Results available

Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA

NCT02814916
View directory record Official record
Conditions
Methicillin-Resistant Staphylococcus Aureus, Bacterial Infections, Staphylococcal Skin Infections
Interventions
Dalbavancin, Vancomycin, Oxacillin, Flucloxacillin, Cefadroxil, Clindamycin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
0 Years to 17 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
15
States / cities
Mobile, Alabama • Phoenix, Arizona • La Palma, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 8, 2026, 4:36 PM EDT
Completed Phase 4 Interventional Results available

Daptomycin Versus Vancomycin in Participants With Skin Infections Due to MRSA

NCT01419184
View directory record Official record
Conditions
Staphylococcal Skin Infections
Interventions
Daptomycin, Vancomycin
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
25
States / cities
Mobile, Alabama • Chula Vista, California • Escondido, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Sep 8, 2026, 4:36 PM EDT
Completed Phase 2 Interventional Results available

GSK1322322 Versus Linezolid in the Treatment of Acute Bacterial Skin and Skin Structure Infection

NCT01209078
View directory record Official record
Conditions
Skin Infections, Bacterial
Interventions
GSK1322322, Linezolid, GSK1322322 placebo, Linezolid placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
7
States / cities
Anniston, Alabama • Chula Vista, California • La Mesa, California + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2017 · Synced Sep 8, 2026, 4:36 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Mupirocin Ointment to Eliminate Nasal Carriage of Staphylococcus Aureus in HIV Infection

NCT00801879
View directory record Official record
Conditions
Staphylococcus Aureus, HIV Infections
Interventions
Mupirocin calcium ointment, 2%, Placebo ointment
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
2
States / cities
New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 28, 2014 · Synced Sep 8, 2026, 4:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I STEBVax in Healthy Adults

NCT00974935
View directory record Official record
Conditions
Toxic Shock Syndrome Staphylococcal
Interventions
Aluminum hydroxide, STEBVax vaccine
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 18, 2015 · Synced Sep 8, 2026, 4:36 PM EDT
Enrolling by invitation Phase 4 Interventional

Does Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes?

NCT07148960
View directory record Official record
Conditions
Staphylococcus Aureus Bacteremia
Interventions
Early Dual IV Antibiotic Therapy - MRSA, Early Dual IV Antibiotic Therapy - MSSA, Single Agent IV Antibiotic Therapy - MRSA, Single Agent IV Antibiotic Therapy - MSSA
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Sep 8, 2026, 4:36 PM EDT
Completed Not applicable Interventional Results available

Cost-Effectiveness Study Comparing Chlorhexidine Bathing With Active Surveillance Cultures to Prevent Methicillin-resistant Staphylococcus Aureus & Other Hospital Infections

NCT00779246
View directory record Official record
Conditions
Staphylococcal Infections
Interventions
Nasal swabs for MRSA culture, Chlorhexidine gluconate, Contact isolation
Other · Drug
Lead sponsor
Christiana Care Health Services
Other
Eligibility
18 Years and older
Enrollment
1,518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Sep 8, 2026, 4:36 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Virulence Determinants in S Aureus Bacteremia

NCT00319826
View directory record Official record
Conditions
Bacteremia
Interventions
No intervention
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
1,354 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 27, 2016 · Synced Sep 8, 2026, 4:36 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of Ceftaroline Fosamil Versus a Comparator in Adult Subjects With Community-acquired Bacterial Pneumonia (CABP) With Risk for Methicillin-resistant Staphylococcus Aureus

NCT01645735
View directory record Official record
Conditions
Infections
Interventions
Ceftaroline fosamil, Ceftriaxone plus vancomycin
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
13
States / cities
Phoenix, Arizona • Sylmar, California • DeLand, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2016 · Synced Sep 8, 2026, 4:36 PM EDT
Completed Not applicable Interventional Results available

Staphylococcus Aureus Decolonization Study

NCT00731783
View directory record Official record
Conditions
Staphylococcal Skin Infections, Abscesses, Furunculosis, Staphylococcus Aureus, MRSA Infection
Interventions
2% Mupirocin Ointment, 4% Chlorhexidine liquid soap, Hygiene protocol
Drug · Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
6 Months to 21 Years
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 29, 2012 · Synced Sep 8, 2026, 4:36 PM EDT